Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials

• Hauptverfasser: Qingfang Li (Verfasst von), Li Cheng (Verfasst von), Kai Shen (Verfasst von), Hongyu Jin (Verfasst von), Hui Li (Verfasst von), Yuan Cheng (Verfasst von), Xuelei Ma (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2019-06-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Background: B-cell leukemia/lymphoma-2 (BCL-2) protein is an important part of apoptotic pathway, which is overexpressed in chronic lymphocytic leukemia cells, non-Hodgkin lymphoma cells, and myeloma cells. Venetoclax (ABT-199/GDC-0199) is a highly selective bioavailable inhibitor of BCL-2 protein,...